📊 Research Summary: The ImmunoSep trial demonstrates the potential for biomarker-guided immunotherapy in a subset of patients with sepsis.

This trial assessed whether immunotherapy tailored to individual immune dysregulation—macrophage activation–like syndrome and sepsis-induced immunoparalysis—could improve organ function among patients with sepsis-3.